Advertisement

Follicle-Stimulating Hormone

  • Tom Sam
  • Renato de LeeuwEmail author
Chapter

Abstract

In this chapter recombinant FSH, follicle-stimulating hormone, products are discussed. Over the years, several different FSH products were introduced, i.e. follitropin alfa, follitropin beta, follitropin delta and corifollitropin alfa. Structural aspects that affect the performance of these highly glycosylated proteins are explained.

Keywords

Follicle stimulating hormone Follitropin alfa Follitropin beta Corifollitropin alfa 

References

  1. De Leeuw R, Mulders J, Voortman G, Rombout F, Damm J, Kloosterboer L (1996) Structure-function relationship of recombinant follicle stimulating hormone (Puregon®). Mol Hum Reprod 2:361–369CrossRefGoogle Scholar
  2. Devroey P, Boostanfar R, Koper NP, Ijzerman P, Mannaerts BMJL, Fauser BC, ENGAGE Investigators (2009) A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 24:3063–3072CrossRefGoogle Scholar
  3. European public assessment report Gonal-F (Follitropin alfa), CPMP/415/95. Revision 18, 11 Apr 2011. European Agency for the Evaluation of Medicinal ProductsGoogle Scholar
  4. Fares FA, Suganuma N, Nishimori K, LaPolt PS, Hsueh AJ, Boime I (1992) Design of a long-acting follitropin agnosit by fusinh the C-terminal sequence of the beta chorionic gonadotropin subunit. Proc Natl Acad Sci USA 89:4304–4308Google Scholar
  5. Fauser BCJM, Mannaerts BMJL, Devroey P, Leader A, Boime I, Baird DT (2009) Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. Hum Reprod Update 15:309–321CrossRefGoogle Scholar
  6. Fauser BCJM, Alper MM, Ledger W, Schoolcraft WB, Zandvliet A, Mannaerts BMJL (2010) Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during controlled ovarian stimulation for in vitro fertilisation. Reprod Biomed Online 21:593–601CrossRefGoogle Scholar
  7. Howles CM (1996) Genetic engineering of human FSH (Gonal-F®). Hum Reprod Update 2:172–191CrossRefGoogle Scholar
  8. LaPolt PS, Nishimori K, Fares FA, Perlas E, Boime I, Hsueh AJ (1992) Enhanced stimulation of follicle stimulating and ovulatory potential by long acting follicle stimulating hormone agonist with extended carboxy-termial peptide. Endocrinology 131:2514–2520CrossRefGoogle Scholar
  9. Mannaerts BMJL, De Leeuw R, Geelen J, Van Ravenstein A, Van Wezenbeek P, Schuurs A, Kloosterboer L (1992) Comparative in vitro and in vivo studies on the biological properties of recombinant human follicle stimulating hormone. Endocrinology 129:2623–2630CrossRefGoogle Scholar
  10. Matzuk MM, Hsueh AJ, Lapolt P, Tsafriri A, Keene JL, Boime I (1990) The biological role of the carboxy-terminal extension of human chorionic gonadotropin (corrected) beta-subunit. Endocrinology 126:376–383CrossRefGoogle Scholar
  11. Norman RJ, Zegers-Hochschild F, Salle BS, Elbers J, Heijnen E, Marintcheva-Petrova M, Mannaerts B (2011) Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity. Hum Reprod 26(8):2200–2208CrossRefGoogle Scholar
  12. Olijve W, de Boer W, Mulders JWM, van Wezenbeek PMGF (1996) Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon®). Mol Hum Reprod 2:371–382CrossRefGoogle Scholar
  13. Olson H, Standström R, Grundemar L (2014) Different pharmacokinetic and pharmodynamic properties of recombinant follicle-stimulating hormone (rFSH) derived from a human cell line compared with rFSH from a non-human cell line. J Clin Pharmacol 54:1299–1307CrossRefGoogle Scholar
  14. Rettenbacher M, Andersen AN, Garcia-Velasco JA, Sator M, Barri P, Lindenberg S, van der Veen K, Khalaf Y, Bentin-Ley U, Obruca A, Tews G, Schenk M, Stowitzki T, Narvekar N, Sator K, Inthurn B (2015) A multi-center phase 3 study comparing efficacy and safety of Bemfola versus Gonal-F in women undergoing ovarian stimulation for ivf. Reprod Biomed Online 30:504–513CrossRefGoogle Scholar
  15. van Wezenbeek P, Draaier J, van Meel F, Olijve W (1990) Recombinant follicle stimulating hormone. I. Construction, selection and characterization of a cell line. In: Crommelin DJA, Schellekens H (eds) From clone to clinic, Developments in biotherapy, vol 1. Kluwer, Dordrecht, pp 245–251CrossRefGoogle Scholar
  16. Verbost P, Sloot WN, Rose UM, de Leeuw R, Hanssen RGJM, Verheijden GFM (2011) Pharmacologic profiling of corifollitropin alfa, the first developed sustained follicle stimulant. Eur J Pharmacol 651:227–233CrossRefGoogle Scholar
  17. Voortman G, van de Post J, Schoemaker RC, Gerwen J v (1999) Bioequivalence of subcutaneous injections of recombinant human follicle stimulating hormone (Puregon®) by Pen-injector and syringe. Hum Reprod 14:1698–1702CrossRefGoogle Scholar

Suggested Reading

  1. Seyhan A, Ata B (2011) The role of corifollitropin alfa in controlled ovarian stimulation for IVF in combination with GnRH antagonist. Int J Women’s Health 3:243–255Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.GlobalPharmCMCHeeschThe Netherlands
  2. 2.DeLeeuw ConsultancyHeeschThe Netherlands

Personalised recommendations